New Directions in the Management of HCC

Richard S. Finn, MD


Professor of Clinical Medicine Division of Hematology/Oncology Director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine at UCLA



The Challenge

- Progress in systemic therapy has been slow
- Incremental improvements with sequential VEGFR TKIs
- Immune checkpoint inhibitors have demonstrated singleagent activity in advanced HCC but phase 3 studies did not meet their endpoints
- How do we improve outcomes with IO in HCC?
 - Biomarker select those patients that are most likely to benefit
 - Novel combinations that increase efficacy

Combining VEGF Inhibition and Anti-PD-1/PD-L1 Agents



- Bevacizumab (anti-VEGF) is an antiangiogenic agent with additional immunomodulatory effects
- In combination, bevacizumab may further enhance atezolizumab's efficacy by reversing VEGF-mediated immunosuppression to promote T-cell infiltration into the tumor

Chen DS, Mellman I. Immunity. 2013;39:1-10. 2. Hegde PS et al. Semin Cancer Biol. 2018;52:117-124. 3. Wallin JJ et al. Nat Commun. 2016;7:12624.
 Goel S et al. Physiol Rev. 2011;91:1071-1121. 5. Motz GT et al. Nat Med. 2014;20:607-615. 6. Hodi FS et al. Cancer Immunol Res. 2014;2:632-642.
 Gabrilovich DI, Nagaraj S. Nat Rev Immunol. 2009;9:162-174. 8. Roland CL et al. PLoS One. 2009;4:e7669. 9. Facciabene A et al. Nature. 2011;475:226-230.
 Voron T et al. J Exp Med. 2015;21:139-148. 11. Gabrilovich DI. Nat Med. 1996;2:1096-1103. 12. Oyama T et al. J Immunol. 1998;160:1224-1232.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, M.D., Shukui Qin, M.D., Masafumi Ikeda, M.D., Peter R. Galle, M.D., Michel Ducreux, M.D., Tae-You Kim, M.D., Masatoshi Kudo, M.D.,
Valeriy Breder, M.D., Philippe Merle, M.D., Ahmed O. Kaseb, M.D., Daneng Li, M.D.,
Wendy Verret, Ph.D., Derek-Zhen Xu, M.D., Sairy Hernandez, Ph.D., Juan Liu, Ph.D.,
Chen Huang, M.D., Sohail Mulla, Ph.D., Yulei Wang, Ph.D., Ho Yeong Lim, M.D.,
Andrew X. Zhu, M.D., Ph.D., and Ann-Lii Cheng, M.D.,
for the IMbrave150 Investigators*

KEYNOTE-524: Lenvatinib+Pembrolizumab Efficacy Outcomes

Parameter	Lenvatinib + Pembrolizumab (N = 100)					
	RECIST v1.1 per IIR					
ORR (confirmed responses), n (%) (95% Cl)ª	36 (36) (26.6–46.2)					
Best overall response, n (%) Complete response Partial response Stable disease ^b Progressive disease Unknown/not evaluable	1 (1) 35 (35) 52 (52) 7 (7) 5 (5)					
Median DOR ^c for confirmed responders, months (95% CI) ^d	12.6 (6.9–NE)					
Median TTR for confirmed responders, months (range)	2.8 (1.2–7.7)					
Disease control rate, n (%) (95% Cl)ª	88 (88) (80.0–93.6)					


^aThe 95% CIs are calculated using an exact method of binomial distribution (Clopper– Pearson method); ^bincludes unconfirmed partial response, noncomplete response/ nonprogressive disease, and durable stable disease; ^cthe Kaplan–Meier method was used for estimating DOR; ^dthe 95% CIs are based on a generalized Brookmeyer and Crowley method. Percentage Change From Baseline in Sum of Diameters of Target Lesions at Postbaseline Nadir (IIR; RECIST v1.1)




^am = number of patients with both baseline and postbaseline values for the sum of diameters of target lesions.

Finn et al JCO 2020.

KEYNOTE-524 Kaplan-Meier Estimates of OS



KEYNOTE-524 Most Common TRAEs^a (≥ 20% of Patients)




^aThere was 1 grade 4 treatment-related AE (leukopenia/neutropenia).
Finn et al JCO 2020.

KEYNOTE-524 Safety

- Median duration of exposure
 - Overall treatment duration^a: 7.9 months (minimum: 0.2; maximum: 31.1)
 - Lenvatinib: 7.6 months (minimum: 0.2; maximum: 31.1)
 - Pembrolizumab: 7.4 months (minimum: 0.03; maximum: 23.5)
- 95% Of patients had ≥ 1 TRAE
- 67% Of patients had grade \geq 3 TRAEs
 - Grade 3: 63%
 - Grade 4: 1% (leukopenia / neutropenia, n = 1)
 - Grade 5: 3% (acute respiratory failure / acute respiratory distress syndrome, n = 1; abnormal hepatic function, n = 1; intestinal perforation, n = 1)

^aThe duration between the earliest start date of the first dose of either medication and the latest date of last dose of either medication.


KEYNOTE-524 Kaplan–Meier Estimates of OS by Best Overall Response (IIR; RECIST v1.1)



• Finn et al EASL 2020.

LEAP-002: First-Line Lenvatinib Plus Pembrolizumab Versus Lenvatinib Plus Placebo in Advanced HCC¹

Phase 3




- **Primary endpoints:** OS and PFS
- Secondary endpoints: ORR, DOR, DCR, and safety

^a 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg).

1. https://clinicaltrials.gov/ct2/show/NCT03713593. Accessed May 13, 2019.


Phase 3 COSMIC-312 Study: Cabozantinib ± Atezolizumab Versus Sorafenib in Advanced HCC¹

Study in Adults With Advanced HCC Who Have Not Received Prior Systemic Anticancer Therapy in the Advanced Setting




1. https://clinicaltrials.gov/ct2/show/NCT03755791. Accessed May 13, 2019.

Revisiting anti-CTLA-4 and anti-PD-(L)1 Combination Strategy



In solid tumors, ICI regimens incorporating higher doses of anti-CTLA-4 combined with anti-PD-(L)1 are often associated with improved OS compared to those with lower doses of anti-CTLA-4 but with increased toxicity.⁴⁻⁹

- High-dose T combined with D results in an initial burst of peripheral T-cells in patients with NSCLC.¹⁰
- Similarly in melanoma, the initial dose of ipilimumab + nivolumab causes a proliferative burst of peripheral Tcells, which is not repeated at subsequent doses.¹¹



Could a single priming dose of tremelimumab with durvalumab improve immune-mediated clinical activity in HCC patients while minimizing toxicity?


1. Huang, et al. *Nature*, 2017. 60-65; 2. Kamphorts, et al. *PNAS*, 2017. 4993-4998; 3. Butte, et al. *Immunity*, 2007. 111-122; 4.Yau, et al. *J Clin Oncol*, 2019. abstr 4012; 5. Naumann, et al. *Ann Oncol*, 2019. v851-v934; 6. Hellmann, et al. *J Cin Oncol*, 2017. abstr 8503; 7. Sharma, et al. *J Clin Oncol*, 2019. 1608-1616; 8. Janjigian, et al. *J Clin Oncol*, 2018. 2836-2844; 9. Weber, et al. *J Clin Oncol*, 2012. 2691-2697; 10. Antonia, et al. *Lancet Oncol*, 2016. 299-308. 11. Souza, et al. *Cancer Res*, 2018. abstr CT 104.



#ASCO20 Slides are the property of the author, permission required for reuse.

PRESENTED BY: R. Katie Kelley, MD


Phase 2 Trial: Tremelimumab and Durvalumab¹



	T300+D (n = 75)	T75+D (n = 84)	D (n = 104)	T (n = 69)
Grade 3/4 TRAEs, %	35.1	24.4	17.8	42.0
Serious TRAEs, %	13.5	11.0	10.9	21.7
Grade 5 TRAEs, n	0	1 ^a	3 ^b	0
Discontinuation due to TRAEs, %	10.8	6.1	7.9	11.6
ORR, % (95% CI)	24.0 (14.9-35.3)	9.5 (4.2-17.9)	10.6 (5.4-18.1)	7.2 (2.4-16.1)
Median DoR, mo	NR	13.2	11.2	24.0

1. Kelley RK et al. ASCO 2020. Abstract 4508.

Responses Observed Regardless of PD-L1 or Viral Status



Courtesy of Richard S Finn, MD

*Responders; M, PD-L1 status missing

PD-L1 status is calculated as total number of tumor cells and tumorassociated immune cells positive for PD-L1 divided by tumor area


2020ASCO PRESENTED AT: ANNUAL MEETING

#ASCO20 Slides are the property of the author. permission required for reuse


PRESENTED BY: R. Katie Kelley, MD

Pharmacodynamic Biomarker Analysis

T300+D Drives an Acute Expansion of CD8+ Lymphocytes that is Associated with Response



Quadratic Discriminant Analysis of 26 lymphocyte populations on day 15 shows that T300+D patients are maximally differentiated by a lymphocyte population predominantly composed of CD3+CD8+Ki67+ T cells




Elevated CD8+Ki67+ T cells on day 15 are associated with CR/PR Highest median CD8+Ki67+ T cells occurred in CR/PR in T300+D arm

PRESENTED AT: 2020ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author permission required for reuse.

PRESENTED BY: R. Katie Kelley, MD

Phase III HIMALAYA Trial: Durvalumab Plus Tremelimumab Versus Sorafenib¹



DOR, and QOL

CheckMate-040: Nivolumab + Ipilimumab Efficacy Results^{1,2}

	Arm A NIVO1/IPI3 Q3W (n = 50)	Arm B NIVO3/IPI1 Q3W (n = 49)	Arm C NIVO3 Q2W/ IPI1 Q6W (n = 49)	ç				— Ar	m B r	nOS	(95%	CI) =	12.5	mo (9. mo (7. mo (7.	6-16.	4
ORR by BICR using RECIST v1.1, n (%)	16 (32)	15 (31)	15 (31)	;	70 -	J. See	- ,, ,,									
BOR, n (%)					60 -		ڡؚڴ		<u> </u>							
CR	4 (8)	3 (6)	0	% ;	50 -		L	᠆᠋᠊ᡶ	`			`	_			
PR	12 (24)	12 (24)	15 (31)	SO	40 -				ᠧ᠆		~					
SD	9 (18)	5 (10)	9 (18)						<u>م</u>	٦			7	~ xx ×		
PD	20 (40)	24 (49)	21 (43)		30 -					<u>ـــــ</u>				(000)	<u> </u>	0
Unable to determine	3 (6)	4 (8)	4 (8)		20 -											
DCR, n (%)	27 (54)	21 (43)	24 (49)		10 -											
Median TTR (range), months	2.0 (1.1–12.8)	2.6 (1.2–5.5)	2.7 (1.2–8.7)		0											
Median DOR (range), months	17.5 (4.6 to 30.5+)	22.2 (4.2 to 29.9+)	16.6 (4.1+ to 32.0+)		0	36	9	12	15	18 Tim	21 e, mo	24	27	30	33	

- Similar ORR, DCR, and DOR were observed across treatment arms
 - Consistently high ORR (>30%) was achieved in all treatment arms
 - In total, 7 patients had complete response (4 in arm A and 3 in arm B)
- Arm A: NIVO1/ IPI3 Q3W \times 4 followed by nivolumab 240 mg IV Q2W flat dose
- Arm B: NIVO3/ IPI1 Q3W × 4 followed by nivolumab 240 mg IV Q2W flat dose
- ORR is defined as CR + PR
- SD does not include 2 patients in arm A and 1 patient in arm B who were reported as non-CR/non-PD
- DCR is defined as CR + PR + SD + non-CR/non-PD

CheckMate-040: Nivolumab + Ipilimumab Treatment-related Adverse Events

Summary of TRAEs	NIVO1/II	m A PI3 Q3W* = 49	NIVO3/IP	n B I1 Q3W** : 49	Arm C NIVO3 Q2W/IPI1 Q6W N = 48			
	Any Grade	Grade 3-4	Any Grade	Grade 3-4	Any Grade	Grade 3-4		
Any TRAE, n(%)	46 (94)	26 (53)	35 (71)	14 (29)	38 (79)	15 (31)		
Pruritus	22 (45)	2 (4)	16 (33)	0	14 (29)	0		
Rash	14 (29)	2 (4)	11 (22)	2 (4)	8 (17)	0		
Diarrhea	12 (24)	2 (4)	6 (12)	1 (2)	8 (17)	1 (2)		
AST increased	10 (20)	8 (16)	10 (20)	4 (8)	6 (13)	2 (4)		
Upase Increased	7 (14)	6 (12)	6 (12)	3 (6)	8 (17)	4 (8)		
Fatigue	9 (18)	1 (2)	6 (12)	0	5 (10)	0		
ALT increased	8 (16)	4 (8)	7 (14)	3 (6)	4 (8)	0		
Hypothyroidism	10 (20)	0	4 (8)	0	4 (8)	0		
Rash maculo- papular	7 (14)	2 (4)	4 (8)	0	3 (6)	0		
Decreased appetite	6 (12)	0	4 (8)	0	3 (6)	0		
Malaise	6 (12)	1 (2)	3 (6)	0	3 (6)	0		
Adrenal insufficiency	7 (14)	1 (2)	3 (6)	0	2 (4)	0		
Nausea	5 (10)	0	4 (8)	0	1 (2)	0		
Pyrexia	2 (4)	0	4 (8)	0	5 (10)	0		

- Rates of any grade TRAEs:
 - 94% Arm A
 - 71% Arm B
 - 79% Arm C
- Types of TRAEs similar across all treatment arms

CheckMate-040: Nivolumab + Ipilimumab Immune-mediated Adverse Events

Summary of IMAEs	NIVO1/I	m A PI3 Q3W* = 49	Arn NIVO3/IP N =	I1 Q3W**	Arm C NIVO3 Q2W/IPI1 Q6W N = 48			
n(%)	Any Grade	Grade 3-4	Any Grade	Any Grade Grade 3-4		Grade 3-4		
Rash	17 (35)	3 (6)	14 (29)	2 (4)	8 (17)	0		
Hepatitis	10 (20)	10 (20)	6 (12)	5 (10)	3 (6)	3 (6)		
Adrenal Insufficiency	9 (18)	2 (4)	3 (6)	0	3 (6)	0		
Diarrhea/colitis	5 (10)	3 (6)	1 (2)	1 (2)	1 (2)	1 (2)		
Pneumonitis [†]	5 (10)	3 (6)	0	0	0	0		
Nephritis/renal dysfunction	0	0	1 (2)	0	1 (2)	1 (2)		
Hypersensitivity	0	0	1 (2)	1 (2)	1 (2)	0		
Hypophysitis	1 (2)	0	0	0	1 (2)	1 (2)		
Hyperthyroidism	0	0	1 (2)	0	1 (2)	0		
Hypothyroidism/ thyroiditis	0	0	0	0	1 (2)	0		
Diabetes mellitus	0	0	0	0	0	0		

- Most common IMAEs in all arms: rash, hepatitis, and adrenal insufficiency
- Arm A had higher rates of IMAEs compared with Arms B and C

CheckMate 9DW

- A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
 - Primary Outcome Measure:
 - Overall Survival (OS)
 - Secondary Outcome Measures:
 - Objective Response Rate (ORR)
 - Duration of Response (DOR)
 - Time to Symptom Deterioration (TTSD)
- Start 9/19
- Primary Completion 9/23


Conclusions


- IMbrave150 trial validated IO in a phase 3 study in combination with VEGF targeting
 - Atezolizumab+bevacizumab
 - Phase III ORIENT-32 trial (China only): sintilimab combined with a bevacizumab biosimilar in patients with advanced HCC
- Other novel combinations are showing promising results in early phase studies
- IO + VEGFR TKIs
 - Lenvatinib+pembrolizumab (LEAP-002)
 - Cabozantinib+atezolizumab (COSMIC-312)
- Anti-PD-1/PD-L1 + Anti-CTLA-4
 - Nivolumab+ipilimumab (CheckMate 9DW)
 - Durvalumab+tremelimumab (HIMALAYA)

Case: Len/pembro for first-line advanced HCC

- 65 y.o. male who presented in late November of 2019, with progressive ascites, and muscle wasting. Ultimately, a CT scan was done on 12/20/19, which showed cirrhotic liver, with multiple enhancing liver lesions, largest 5.5cm compressing and invading his IVC.
- Labs done on 1/2/20 showed AFP of 1357, and positive for Hep C. Previous to this, he states he was not aware of being Hep C positive, but did use IV drugs in his teen years.
- WBC 7.0, Hgb 15.7, plts 89, Cr 0.5, T bili 1.4, Alb 3.8, AST 96, ALT 38.
- ECOG PS 2.

Case: Len/pembro for first-line advanced HCC, continued





Case: Len/pembro for first-line advanced HCC, continued

- Have discussion, pt with very advanced HCC with invasion into the RA
- CP A6/ B7 (from ascites)
- Needs a response and quickly
- Start len 12 mg + pembro Feb 2020
- T bili slowly rises, peaking at 4.6 in March and len held, wt loss
- AFP rapidly declines
- T bili starts falling and len resumed at
 4 mg then titrated to 8 mg

1/23/20 0838 - 5/15/20 1518) × 450 4000 3500 3000 2500 3 2000 1500 1000 500 0022 2/15/20 1606 3/8/20 0750 3/31/20 2334 4/22/20 1518 5/15/20 0838 1/23/20

AFP over time

Case: Len/pembro for first-line advanced HCC, continued

- Overall improving energy, decreased ascites, stopped using walker
- Reimaged May 2020 after C5 pembro
 - Significant response
- Ongoing response, 2021

